anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and system for managing a treatment for a subject diagnosed with a sarcoma disease state. Peptide structure data corresponding to a biological sample obtained from the subject is received. A response score that predicts a likelihood of responsiveness to the treatment is computed using quantification data identified from the peptide structure data for a set of peptide structures. The set of peptide structures includes at least one peptide structure identified from a plurality of peptide structures listed in Table 1. The plurality of peptide structures is listed in Table 1 with respect to relative significance to a survival for the sarcoma disease state. A treatment response output is generated based on the response score.
Demographic information will be collected prior to study participation and include age, sex, education, family medical history, past medical history, concussion history, litigious status and medication use. The PAR-Q+ questionnaire will be completed to determine readiness for exercise by a physician. Baseline questionnaires will be completed, such as the Fatigue Severity Scale (FSS), Generalized Anxiety Disorder Scale (GAD-7), Headache Intensity Scale-6 (HIT-6), Patient Health Questionnaire(PHQ-9), Epworth Sleepiness Scale(ESS) and Quality of Life After Brain Injury(QOLIBRI), Rivermead Post Concussion Symptoms Questionnaire (RPQ), Modified Godin Leisure-Time Exercise Questionnaire(GLTQ), Rapid Assessment Disuse Index (RADI) and Postconcusion Syndrome Checklist (PCSC). Pre- and post-intervention blood samples will be collected from all participants. Participants will be asked to perform a tactile assessment pre- and post-intervention. Sleep will be monitored using wrist-based actigraphy and a sleep diary for 3-6 days/nights prior to the intervention start and for five days following completion of the exercise protocol. Pre and post magnetic resonance spectroscopy (MRS) will also be completed. Participants will be randomized to a structured aerobic exercise protocol (AEP) or stretching protocol, followed by aerobic exercise protocol(SP+AEP) with a random number generator. Both groups will undergo exercise testing using the Buffalo Concussion Treadmill Test to determine exercise prescription. Upon completion of SP, participants will continue on to the AEP and complete it in full. Following the exercise protocols, all questionnaires will be completed post-intervention. At 3 and 9 weeks following protocol completion, online follow surveys will be completed to assess symptom burden (RPQ, QOLIBRI, HIT-6, ESS, FSS) along with questions regarding current exercise.
Disclosed is; the use of mebendazole (MBZ, Vermox) as a Ran inhibitor and as a treatment for cancer than overexpresses RAN (e.g. triple negative breast cancer). Preferably, MBZ is used in combination with a tyrosine kinase inhibitor (TKI); more preferably; the TKI is an inhibitor of EGFR or Bcr-Abl; most preferably, the TKI is gefitinib (Iressa) or one of (afatinib, axitinib, bosutinib, crizotinib, dasatinib, erlonib, osimertinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, sorafenib, sunitinib, ibrutinib). The MBZ and TKI may be administered sequentially, simultaneously, or separately. More broadly, use of any Ran inhibitor in combination with any tyrosine kinase inhibitor is claimed; apparently, use of mebendazole serves to overcome resistance to the TKI. Also claimed is the use of mebendazole (monotherapy) as an immunotherapy, most preferably an immunotherapy used to downregulate C5a.
The invention provides a ginger giant salamander peptide simplified health care prescription and a preparation method of an effervescent tablet thereof, belonging to the field of nutritional supplements. The prescription mainly comprises three medicinal and edible traditional Chinese medicine components of monarch drug ginger, ministerial drug turmeric and adjuvant and guide drug red date, and the content range of each component in each effervescent tablet single dose is defined. In addition, the giant salamander peptide can be selectively added as a functional component. The prescription realizes the effects of dispersing wind-cold and conditioning the body through reasonable proportion and fine production process. The invention also provides a detailed method for preparing the prescription effervescent tablet, which comprises the steps of decocting the traditional Chinese medicine components to form decoction, freeze-drying the decoction to form freeze-dried powder, mixing the freeze-dried powder with a proper amount of additives, and finally pressing and forming. The invention provides a health-preserving prescription which is convenient to carry, easy to take and definite in efficacy for consumers.
BACKGROUND: Hearing loss is associated with restricted physical activity (PA) and impaired physical functioning, yet the relationship between severity of hearing impairment (HI) and novel PA measures in older adults with untreated HI is not well understood.
METHODS: Analyses included 845 participants aged ≥70 years (mean = 76.6 years) with a better-hearing ear pure-tone average (PTA) ≥30 and <70 dB in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study who wore an ActiGraph accelerometer for 7 days. Physical functioning measures included grip strength and the Short Physical Performance Battery (SPPB). Linear regression models estimated the association by HI level (moderate or greater [PTA ≥ 40 dB] vs mild [PTA < 40 dB]) and continuous hearing with total daily activity counts, active minutes/day, activity fragmentation, grip strength, and gait speed. Logistic regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs) of poor performance on the SPPB (≤6) and its subtests (≤2). Mixed-effects models estimated differences by HI level in activity by time of day.
RESULTS: Participants with moderate or greater HI had poorer physical functioning, particularly balance (OR = 2.17, 95% CI = 1.29-3.67), versus those with mild impairment. There was no association of HI level with activity quantities or fragmentation. For diurnal patterns of activity, participants with moderate or greater HI had fewer activity counts in the afternoon (12:00 pm -05:59 pm).
CONCLUSIONS: Older adults with worse hearing had shifted diurnal patterns and poorer balance performance. Exercise programs should be tailored to older adults with different levels of HI to maintain PA and physical functioning, particularly balance control.
FIELD: medicine. ^ SUBSTANCE: invention refers to an application of hydrophilic biologically compatible adhesives in drug delivery systems, in wound dressings, in bioelectrodes and in the other systems wherein hydrophilic biologically compatible adhesives are desired. Particularly, the invention refers to water-swelling, water-insoluble polymers which in combination make the composition adhesive in moisture contact. in which a first water-swelling, water-insoluble polymer is cationic, a second water-swelling, water-insoluble polymer is anionic, and polymers are ion bonded to each other with forming a polymer matrix. ^ EFFECT: hydrophilic biologically compatible adhesives are adhered to a body surface with coherence preserved. ^ 24 cl
BACKGROUND: Growth associated protein-43 (GAP-43) and neurofilaments light (NFL) are biomarkers of synaptic and axonal injury, and are associated with cognitive decline in Alzheimer's disease (AD) contiuum. We investigated whether Polygenic Hazard Score (PHS) is associated with specific biomarkers and cognitive measures, and if it can predict the relationship between GAP-43, NFL, and cognitive decline in AD.
METHOD: We enrolled 646 subjects: 93 with AD, 350 with mild cognitive impairment (MCI), and 203 cognitively normal controls. Variables included GAP-43, plasma NFL, and PHS. A PHS of 0.21 or higher was considered high risk while a PHS below this threshold was considered low risk. A subsample of 190 patients with MCI with four years of follow-up cognitive assessments were selected for longitudinal analysis . We assessed the association of the PHS with AD biomarkers and cognitive measures, as well as the predictive power of PHS on cognitive decline and the conversion of MCI to AD.
RESULTS: PHS showed high diagnostic accuracy in distinguishing AD, MCI, and controls. At each follow-up point, high risk MCI patients showed higher level of cognitive impairment compared to the low risk group. GAP-43 correlated with all follow-up cognitive tests in high risk MCI patients which was not detected in low risk MCI patients. Moreover, high risk MCI patients progressed to dementia more rapidly compared to low risk patients.
CONCLUSION: PHS can predict cognitive decline and impacts the relationship between neurodegenerative biomarkers and cognitive impairment in AD contiuum. Categorizing patients based on PHS can improve the prediction of cognitive outcomes and disease progression.
Serine/arginine repetitive matrix 2 (SRRM2) has been implicated in tumorigenesis, cancer development, and drug resistance through aberrant splicing; however, its correlation with multiple myeloma (MM) has not been reported. We investigated the potential of SRRM2 as a biomarker and immunotherapeutic target in MM by examining its expression in MM cells using flow cytometry. Our study included 95 patients with plasma cell disease, including 80 MM cases, and we detected SRRM2 expression on plasma cells and normal blood cells to analyze its relationship with clinical profiles. We found widespread positive expression of SRRM2 on plasma cells with little expression on normal blood cells, and its expression on abnormal plasma cells was higher than that on normal plasma cells. Comparative analysis with clinical data suggests that SRRM2 expression on plasma cells correlates with MM treatment response. MM patients with high SRRM2 expression had higher levels of serum β2-mg and LDH, ISS staging, and plasma cell infiltration, as well as high-risk mSMART 3.0 stratification and cytogenetic abnormalities, particularly 1q21 amplification. In patients with previous MM, high SRRM2 expression on plasma cells was associated with higher plasma cell infiltration, high-risk mSMART 3.0 risk stratification, cytogenetic abnormalities, more relapses, and fewer autologous stem cell transplant treatments. In summary, SRRM2 may serve as a novel biomarker and immunotherapeutic target for MM. Its expression level on plasma cells can help in risk stratification of MM and monitoring of treatment response.
PROBLEM TO BE SOLVED: To obtain the subject preparation having excellent improving effects on surface roughening by including a specific aminoethyl compound and tranexamic acid or its salt and/or its derivatives in the preparation. SOLUTION: This preparation contains 0.001-0.3wt.%. of ingredient (A) one or two kinds of aminoethyl compound of the formula NH2 CH2 CH2 X (X is -SO2 H or -SO2 SH), e.g. 2-aminoethylsulfinic acid where X is -SO2 H and/or 2- aminoethylthiosulfonic acid where X is -SO2 SH, and 0.1-10wt.%. of ingredient (B) tranexamic acid or its salt and/or its derivatives. The metal salt of tranexamic acid and its sulufates are listed as examples of tranexamic acid salt and vitamin A acid ester is cited as an example of tranexamic acid derivatives. A moisture retaining agent, a ultraviolet A absorbing agent, ultraviolet ray blocking agent, whitening agent and anti-inflummatory agent may be formulated to the subject preparation.
The invention discloses a product for preventing and/or treating prostate cancer. The product capable of preventing and/or treating the prostate cancer comprises active ingredients, wherein the active ingredients are substances taking signal paths activated or mediated by a gene EphA3, a protein EphA3 and the gene EphA3 and/or the signal paths activated or mediated by the protein EphA3. The method further discloses 1504-RNAi, which knocks an EphA3 gene expression down. Experiments show that the RNAi molecule can block the multiplication of prostate cancer cells, improve the adhesion of the cells and reduce the motion transfer capability of the cancer cells, and can block the differentiation of prostate cancer molecules to neuroendocrine molecules so as to inhibit the transformation of the prostate cancer from androgen dependence to androgen independence. Researches on a molecular mechanism of the 1504-RNAi show that the 1504-RNAi can inhibit the AKT and ERK signal paths widely activated in tumor cells, and a theoretical foundation is laid for the tumor development blocking of the 1504-RNAi. Therefore, the product for preventing and/treating the prostate cancer has vast application prospect in the field of the prevention and treatment of the prostate cancer.
There will be a total of 8 test session. Each session will last for 3.5 hours. At each test session, volunteers will be served with test meal and blood will be collected. After an overnight fast, subjects will visit the research center. Two fasting capillary blood samples will be collected via fingerprick. Following the fasting samples, subject will consume the test meals. Further blood samples will be collected at 15, 30, 45, 60, 90, 120, 150, 180 minutes after the ingestion of test meal. These samples will be used to analyses for whole capillary blood glucose. At every 30 minute interval, samples will be collected for analysis of capillary plasma insulin.
Schizophrenic individuals have higher urinary cotinine levels compared to non-schizophrenic individuals with a similar smoking history. This suggests that schizophrenic individuals may absorb higher doses of nicotine. The purpose of this study is to determine whether smokers with schizophrenia or schizoaffective disorder have higher serum nicotine and cotinine levels in comparison to smokers without schizophrenic-related disorders.

This observational, case-control study will enroll 150 participants, of which 100 will be smokers with schizophrenic-related disorders and 50 will be smokers without a mental illness. Upon completing baseline assessments, participants will smoke a single cigarette. Approximately two minutes following, 3 to 4 ounces of blood will be analyzed for nicotine and cotinine levels. An expired carbon monoxide reading will also be measured. This measurement correlates with the amount of smoke inhalation. Individual participant studies will be completed in 1 to 2 hour-long sessions.
Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
BACKGROUND: Sex differences in oxidative stress-associated cognitive decline are influenced by sex hormone levels. Notably, oxidative stress-associated neuronal cell death can be exacerbated through testosterone signaling via membrane androgen receptor AR45, which is complexed with G protein Gαq within plasma membrane-associated lipid rafts. The objective of this study was to elucidate the impact of sex on the expression of AR45 and Gαq in brain regions associated with cognitive function, specifically hippocampus subregions and entorhinal cortex. Additionally, we investigated whether chronic intermittent hypoxia (CIH), an oxidative stressor with sex-specific effects, would modulate AR45 and Gαq expression in these brain regions.
METHODS: Adult male and female Sprague-Dawley rats were exposed to CIH or normoxia (room air) during their sleep phase for 14 days. We quantified AR45 and Gαq protein expression in various cognition-associated brain regions [dorsal hippocampal CA1, CA3, dentate gyrus (DG), and entorhinal cortex (ETC)] via western blotting. For comparisons, AR45 and Gαq protein expression were also assessed in brain regions outside the hippocampal-ETC circuit [thalamus (TH) and striatum (STR)].
RESULTS: The highest AR45 levels were expressed in the hippocampal CA1 and DG while the lowest expression was observed in the extrahippocampal STR. The highest Gαq levels were expressed in the hippocampal-associated ETC while the lowest expression was observed in the extrahippocampal TH. Females expressed higher levels of AR45 in the hippocampal DG compared to males, while no sex differences in Gαq expression were observed regardless of brain region assessed. Moreover, there was no effect of CIH on AR45 or Gαq expression in any of the brain regions examined. AR45 expression was positively correlated with Gαq expression in the CA1, DG, ETC, TH, and STR in a sex-dependent manner.
CONCLUSION: Our findings reveal enrichment of AR45 and Gαq protein expression within the hippocampal-ETC circuit, which is vulnerable to oxidative stress and neurodegeneration during cognitive decline. Nonetheless, CIH does not modulate the expression of AR45 or Gαq. Importantly, there are sex differences in AR45 expression and its association with Gαq expression in various brain regions, which may underlie sex-specific differences in cognitive and motor function-associated declines with aging.
BACKGROUND: Cardiac surgery with cardiopulmonary bypass (CPB) is associated with hemolysis. Yet, there is no easily available and frequently measured marker to monitor this hemolysis. However, carboxyhemoglobin (CO-Hb), formed by the binding of carbon monoxide (a product of heme breakdown) to hemoglobin, may reflect such hemolysis. We hypothesized that CO-Hb might increase after cardiac surgery and show associations with operative risk factors and indirect markers for hemolysis.
METHODS: We conducted a retrospective descriptive cohort study of data from on-pump cardiac surgery patients. We analyzed temporal changes in CO-Hb levels and applied a generalized linear model to assess patient characteristics associated with peak CO-Hb levels. Additionally, we examined their relationship with red blood cell (RBC) transfusion and bilirubin levels.
RESULTS: We studied 38,487 CO-Hb measurements in 1735 patients. CO-Hb levels increased significantly after cardiac surgery, reaching a peak CO-Hb level 2.1 times higher than baseline ( P < .001) at a median of 17 hours after the initiation of surgery. Several factors were independently associated with higher peak CO-Hb, including age ( P < .001), preoperative respiratory disease ( P = .001), New York Heart Association Class IV ( P = .019), the number of packed RBC transfused ( P < .001), and the duration of CPB ( P = .002). Peak CO-Hb levels also significantly correlated with postoperative total bilirubin levels (Rho = 0.27, P < .001).
CONCLUSIONS: CO-Hb may represent a readily obtainable and frequently measured biomarker that has a moderate association with known biomarkers of and risk factors for hemolysis in on-pump cardiac surgery patients. These findings have potential clinical implications and warrant further investigation.
Although there are various physiotherapy interventions in scleroderma rehabilitation, there is no definitive guideline. Passive and active stretching has been shown to help maintain range of motion (ROM) and optimal length of structures. Home exercises form part of rehabilitation in most studies. The only study in the literature that examined connective tissue massage in patients with scleroderma is by Bongi et al. In this study, connective tissue massage and Mc Mennell joint manipulation technique were applied to the experimental group in addition to the home exercise program. The control group was offered only a home exercise program. The results of the study showed that the group in which connective tissue massage and Mc Mennell joint manipulation technique were applied were effective on hand functions, quality of life and mobility. The aim of our study was to examine the effects of connective tissue massage applied in addition to the exercise program.The study will include 30 patients diagnosed with scleroderma according to American College of Rheumatology/European League Against Rheumatism criteria and followed up in Fırat University Rheumatology Department. Patients will be divided into two groups; 15 patients in the first group will be applied connective tissue massage to the hand and forearm area in addition to the exercise program for hand rehabilitation. In the second group, 15 patients will only receive an exercise program. Range of motion, skin thickness and hand mobility test will be evaluated.
FIELD: medicine; psychoneurology; treatment of epileptics. SUBSTANCE: patients undergo-general-purpose clinical medicamentous therapy by administering dehydration preparations every other day. Each treatment course includes 10 therapeutic sessions. Intervals between courses are arranged first for 3 weeks, but later, as clinical picture improves, intervals are extended to 7-8 weeks. Example: diacarb is administered at rate 1 tablet x 1 time every other day, in total 10 times, after 3-week interval concoction of herbs (valerian root, Sage, Leonurus, St.john's. wort) in small doses of 200 ml during day-tine, every other day, in total 10 times; after three-week interval, again dicarb or other diuretic (magnesium sulfide, triampur, glycerol, etc.) are administered. To accelerate normalization of somatic and neuropsychic habit and social adjustment of epileptic patents, they are additionally subjected to acupuncture treatment using helium-neon laser at wavelength 0.63 mcm, power density 10-20 MWt/sq.cm, exposure time 10-15 s, laser irradiation sessions being effected every 2nd or 3rd day to irradiate points having generally revitalizing or specifically oriented effect. 3-4 points irradiated per session from both sides. Laser treatment course includes 10 sessions and, if need be, repeated courses may be prescribed after 3-6 months. EFFECT: epilepsy attacks become rarer; stable remission achieved; somatic-neutropsychic condition and social adjustment of epileptics improved.
Participants will receive fixed dose combination (FDC) tablet of DOR/ISL (100 mg/0.25 mg) taken once daily (QD) orally from Day 1 to Week 96. After Week 96, eligible participants may continue on DOR/ISL until week 240 or until DOR/ISL becomes commercially accessible, whichever comes first.